Cargando…

KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment

BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Normanno, Nicola, Pinto, Carmine, Castiglione, Francesca, Bardelli, Alberto, Gambacorta, Marcello, Botti, Gerardo, Nappi, Oscar, Siena, Salvatore, Ciardiello, Fortunato, Taddei, GianLuigi, Marchetti, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244430/ https://www.ncbi.nlm.nih.gov/pubmed/22216189 http://dx.doi.org/10.1371/journal.pone.0029146

Ejemplares similares

External quality assessment for EGFR mutations in Italy: improvements in performances over the time
por: Normanno, Nicola, et al.
Publicado: (2017)

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences
por: Normanno, Nicola, et al.
Publicado: (2015)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016
por: van Krieken, Han, et al.
Publicado: (2016)

KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting
por: Barone, Carlo, et al.
Publicado: (2014)

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2016)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

Changes in the Histology of Lung Cancer in Northern Italy: Impact on Incidence and Mortality
por: Mangone, Lucia, et al.
Publicado: (2023)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence
por: Martinelli, Domenico, et al.
Publicado: (2020)

Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era
por: Ciardiello, D., et al.
Publicado: (2022)

The Impact of COVID-19 on New Kidney Cancer Diagnosis: Stage and Treatment in Northern Italy
por: Mangone, Lucia, et al.
Publicado: (2023)

Incidence and Survival of Testicular Cancers in a Province in Northern Italy and Their Association with Second Tumors
por: Mangone, Lucia, et al.
Publicado: (2023)

AXL is an oncotarget in human colorectal cancer
por: Martinelli, Erika, et al.
Publicado: (2015)

Surgery in Small-Cell Lung Cancer
por: Martucci, Nicola, et al.
Publicado: (2021)

Characterization of respiratory infection viruses in hospitalized children from Naples province in Southern Italy
por: Botti, Chiara, et al.
Publicado: (2018)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Effects of COVID‐19 lockdown on arrhythmias in patients with implantable cardioverter‐defibrillators in southern Italy
por: Ducceschi, Valentino, et al.
Publicado: (2022)

Exploring the links between cancer and placenta development
por: Costanzo, Vincenzo, et al.
Publicado: (2018)

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
por: Sacco, Alessandra, et al.
Publicado: (2020)

Assessment of Multi-Mycotoxin Exposure in Southern Italy by Urinary Multi-Biomarker Determination
por: Solfrizzo, Michele, et al.
Publicado: (2014)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine
por: Dotolo, Serena, et al.
Publicado: (2021)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
por: Ciardiello, Davide, et al.
Publicado: (2022)

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
por: Ali, Moiez, et al.
Publicado: (2017)

KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma
por: Vannucchi, Margherita, et al.
Publicado: (2023)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2018)

Reply letter in response to “Letter to the editor in response to: Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence, Martinelli D et al., Human Vaccines & Immunotherapeutics 2020” by Carias and colleagues
por: Marchetti, Federico, et al.
Publicado: (2021)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Compassionate use programs in Italy: ethical guidelines
por: De Panfilis, Ludovica, et al.
Publicado: (2018)

Sequence Analysis of the UCP1 Gene in a Severe Obese Population from Southern Italy
por: Labruna, Giuseppe, et al.
Publicado: (2011)

Chemical and Functional Characterization of Propolis Collected from Different Areas of South Italy
por: Grassi, Giulia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6o94qh2lo0khfna1d47511jgig